Q4 2024 Nuwellis Inc Earnings Call Transcript
Key Points
- Nuwellis Inc (NUWE) reported a 21% increase in consumables utilization, indicating growing adoption of their Aquadex system.
- The company achieved 35% year-over-year revenue growth in their critical care business, driven by higher console sales and consumable utilization.
- A recent peer-reviewed publication in JACC: Heart Failure demonstrated a 60% reduction in heart failure events at 30 days for patients using Aquadex therapy compared to traditional IV diuretics.
- Nuwellis received a favorable reimbursement change from CMS, increasing the facility reimbursement fee for Aquadex ultrafiltration therapy nearly fourfold, effective January 1, 2025.
- The company has no debt on its balance sheet, providing financial stability and flexibility for future initiatives.
- Nuwellis Inc (NUWE) experienced a 9% decline in revenue for the fourth quarter of 2024 due to lower US console sales and international sales.
- Heart failure and pediatric customer categories saw revenue declines of 36% and 20%, respectively, due to lower console sales.
- The company had a voluntary recall of specific lots of blood circuit units, resulting in a non-recurring expense of approximately $150,000.
- Operating loss for the fourth quarter was $2.4 million, although this was an improvement from the previous year.
- The REVERSE-HF trial enrollment and the start of the Vivian clinical trial remain difficult to gauge, indicating potential delays in clinical validation efforts.
Good morning and welcome to the Nuwellis earnings conference call for the fourth quarter and full year ended December 31, 2024. (Operator Instructions)
Participants of this call are advised that the audio of this conference call is being broadcast live over the internet and is also being recorded for playback purposes. A replay of the call will be available approximately one hour after the end of the call.
I would now like to turn the conference over to Vivian Cervantes, Investor Relations, Gilmartin Group. Please go ahead.
Thank you, operator. Good morning, everyone. Thank you for joining us on today's conference call to discuss Nuwellis' corporate developments and financial results for the fourth quarter and full year December 31, 2024. In addition to myself, with us today are John Erb, Nuwellis' Chairman of the Board and Interim CEO as well as Rob Scott, CFO.
At 8:00 Eastern Time today, Nuwellis released financial results for the fourth quarter and full year 2024. If you
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
